Abstract
Seven patients with anti-aquaporin-4 antibody–positive neuromyelitis optica (NMO) or NMO spectrum disorders were recruited on the basis of their limited responsiveness to their current treatment. This study showed that monthly IV injections of tocilizumab, an anti–interleukin-6 receptor antibody, reduced relapses, neurogenic pain, and fatigue in patients with NMO. See p. 1302 From editorialists Rose-John & Gold: “Given the expression pattern of IL-6, targeting the bioactivity of this cytokine is a rational therapeutic approach for the treatment of autoimmune diseases.” See p. 1294 Combining advanced structural and functional imaging …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.